Hansoh Pharmaceutical Group Co (HKSE:03692) EBIT per Share : HK$0.70 (TTM As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Hansoh Pharmaceutical Group Co EBIT per Share?

Hansoh Pharmaceutical Group Co's EBIT per Share for the six months ended in Dec. 2023 was HK$0.41. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.70.

During the past 12 months, the average EBIT per Share Growth Rate of Hansoh Pharmaceutical Group Co was -1.90% per year. During the past 3 years, the average EBIT per Share Growth Rate was -3.30% per year. During the past 5 years, the average EBIT per Share Growth Rate was 1.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Hansoh Pharmaceutical Group Co's EBIT per Share or its related term are showing as below:

HKSE:03692' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -3.3 Med: 11.1 Max: 17.9
Current: -3.3

During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of Hansoh Pharmaceutical Group Co was 17.90% per year. The lowest was -3.30% per year. And the median was 11.10% per year.

HKSE:03692's 3-Year EBIT Growth Rate is ranked worse than
67.75% of 859 companies
in the Drug Manufacturers industry
Industry Median: 7.5 vs HKSE:03692: -3.30

Hansoh Pharmaceutical Group Co's EBIT for the six months ended in Dec. 2023 was HK$2,518 Mil.

Hansoh Pharmaceutical Group Co EBIT per Share Historical Data

The historical data trend for Hansoh Pharmaceutical Group Co's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansoh Pharmaceutical Group Co EBIT per Share Chart

Hansoh Pharmaceutical Group Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

0.61

0.63

0.68

0.57

0.70

Hansoh Pharmaceutical Group Co Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT per Share	Get a 7-Day Free Trial									0.36	0.31	0.28	0.28	0.41

Hansoh Pharmaceutical Group Co EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Hansoh Pharmaceutical Group Co's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	4192.273	/	6019.650
=	0.70

Hansoh Pharmaceutical Group Co's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	2518.112	/	6095.751
=	0.41

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.70

Hansoh Pharmaceutical Group Co (HKSE:03692) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Hansoh Pharmaceutical Group Co EBIT per Share Related Terms

Thank you for viewing the detailed overview of Hansoh Pharmaceutical Group Co's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Hansoh Pharmaceutical Group Co (HKSE:03692) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hansoh Pharmaceutical Group Co Ltd (HKSE:03692) » Definitions » EBIT per Share

Traded in Other Exchanges

3KY:Germany

Address

287 Xiangke Road, Pudong New District, Shanghai, CHN, 201210

Website

https://www.hspharm.com

Hansoh Pharmaceutical Group Co Ltd is a research and development-driven pharmaceutical company in China. The company holds a broad, diversified drug portfolio in CNS diseases, oncology, anti-infectives, and diabetes. Further, it also focuses on metabolic diseases and anti-tumor. The majority of revenue is generated from the sale of pharmaceutical products in Mainland China.

Executives

Cen Junda	2307 Founder of a discretionary trust who can infl
Cantrust (far East) Limited	2301 Trustee
Jqc Holding Limited	2201 Interest of corporation controlled by you
Jqc International Limited	2201 Interest of corporation controlled by you
Sun Yuan	2101 Beneficial owner
Harmonia Holding Investing (ptc) Limited	2201 Interest of corporation controlled by you
Stellar Infinity Company Ltd.	2101 Beneficial owner
Sunrise Investment Advisors Limited	2201 Interest of corporation controlled by you
Zhong Huijuan	2307 Founder of a discretionary trust who can infl
Apex Medical Company Ltd.	2101 Beneficial owner

Hansoh Pharmaceutical Group Co (HKSE:03692) Headlines

No Headlines